Abstract:Few new therapeutics exist to target airway inflammation in mild-to-moderate asthma. Alveolar macrophages regulate airway inflammation by producing proresolving eicosanoids. We hypothesized that stimulation of the purinergic receptor P2X7 in macrophages from individuals with asthma produces eicosanoids associated with airway inflammation and resolution, and that these responses are predicted, in part, by P2X7 pore function. Study subjects were recruited in an Institutional Review Board (IRB)-approved study. Alveolar macrophages were recovered from bronchoalveolar lavage fluid following bronchoscopy. Purinergic receptor classification was performed using flow cytometry and fluorescent cell assay. Macrophages were stimulated in vitro and eicosanoids were measured via ELISA or enzyme immunoassay (EIA) in the presence and absence of P2X7-specific agonist [2'(3')-O-(4-Benzoylbenzoyl)adenosine-5'-triphosphate tri(triethylammonium) salt (Bz-ATP)] and antagonist (AZD9056). Functional P2X7 pore status was confirmed in a live cell assay using P2X7-specific agonists and antagonists. Alveolar macrophages produced increased quantities of the oxylipins lipoxin A4 (LXA4), resolvin D1 (RvD1), and 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) following stimulation with Bz-ATP compared with vehicle controls, responses that were attenuated in the presence of the P2X7-selective antagonist, AZD9056. LXA4 and RvD1 production was greatest at 1 h, whereas 15(S)-HETE was maximally produced 24 h. Prostaglandin E-2 and resolvin E1 were minimally produced by P2X7 activation, indicating differential signaling pathways involved in eicosanoid production in alveolar macrophages derived from individuals with asthma. The early production of the proresolving eicosanoids, LXA4 and resolvin D1, is regulated by P2X7, whereas generation of the proinflammatory eicosanoid, 15(S)-HETE, is only partially regulated through P2X7 signaling and reaches maximal production after the peak in proresolving eicosanoids.NEW & NOTEWORTHY Alveolar macrophages obtained from individuals with asthma produce soluble lipid mediators in response to P2X7 purinergic receptor signaling. Proinflammatory mediators may contribute to asthma exacerbations but proresolving mediators may help with resolution of asthma loss of control. These specialized proresolving lipid mediators may serve as future potential therapeutics for asthma exacerbation resolution and recovery.

Eicosanoid receptors as therapeutic targets for asthma

Prostanoids in Asthma and COPD: Actions, Dysregulation, and Therapeutic Opportunities

Cys-leukotrienes mediate lung dysfunction but not histopathologies in an IL-5/Eotaxin-2 double transgenic mouse model of severe asthma

Could Arachidonic Acid-Derived Pro-Resolving Mediators Be a New Therapeutic Strategy for Asthma Therapy?

Arachidonic Acid Metabolites: Mediators of Inflammation in Asthma

Targeting the OXE receptor as a potential novel therapy for asthma

Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models

Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma

G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action

Cysteinyl Leukotrienes in Allergic Inflammation

Eosinophils Target Therapy for Severe Asthma: Critical Points

New Targeted Therapies for Uncontrolled Asthma

Biologics or immunotherapeutics for asthma?

[New Therapeutic Targets and Drugs for the Severe Asthma]

IgE and eosinophils as therapeutic targets in asthma

Can GPCRs Be Targeted to Control Inflammation in Asthma?

Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons

Emerging interleukin receptor antagonists for the treatment of asthma

The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation

RhoA/Rho-kinases in Asthma: from Pathogenesis to Therapeutic Targets

P2X7 signaling influences the production of pro-resolving and pro-inflammatory lipid mediators in alveolar macrophages derived from individuals with asthma